It has been shown that increased exposure of DAMPs such as calreticulin on the plasma membrane of AML malignant blast cells is a novel powerful prognostic biomarker in AML patients, reflecting activation of clinically relevant AML-specific immune responses [9]. Here, CALR is linked to acute myeloid leukemia.